말단비대증 치료 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 약제별, 투여 경로별, 유통 채널별, 지역별 및 경쟁(2021-2031년)

The Global Acromegaly Treatment Market is projected to expand from USD 1.72 Billion in 2025 to USD 2.57 Billion by 2031, registering a CAGR of 6.92%. This market includes pharmacological, radiological, and surgical interventions-specifically somatostatin analogs and growth hormone receptor antagonists-aimed at regulating hormonal hypersecretion typically caused by pituitary adenomas. Growth is primarily fueled by the introduction of advanced therapeutic formulations that improve patient compliance, as well as increased diagnosis rates due to better screening technologies. Data from the Endocrine Society in 2025 indicated that acromegaly patients face a 3.3 times higher risk of leukemia or lymphoma compared to the general population, highlighting the critical need for effective disease management to prevent severe comorbidities.

However, market expansion is significantly hindered by the prohibitive costs of lifelong pharmacological therapy, which limits patient access in regions with inadequate healthcare reimbursement systems. The financial burden of these essential, indefinite treatments restricts the ability of many patients to receive consistent care. Consequently, these economic constraints impede the broader reach and potential revenue realization of the global market, particularly in developing areas where funding frameworks cannot support such expensive, long-term regimens.

Market Driver

The commercialization of novel oral and long-acting therapeutics is reshaping the Global Acromegaly Treatment Market by addressing the challenges of chronic injectable regimens. Pharmaceutical developers are prioritizing non-peptide oral formulations and extended-release injectables to enhance patient quality of life and compliance, effectively reducing the logistical burdens of lifelong therapy. This shift toward patient-centered innovation is supported by strong clinical trial retention; for instance, Crinetics Pharmaceuticals reported at 'ENDO 2025' in July 2025 that 97.2% of eligible participants in the PATHFNDR-2 study chose to continue with the oral drug paltusotine, signaling a robust demand for non-invasive options.

Simultaneously, the widespread adoption of advanced biomarkers and diagnostic imaging is driving market growth by facilitating earlier detection and timely intervention. Enhanced screening protocols in specialized endocrinology centers are identifying previously undiagnosed patients, leading to increased prescription volumes for targeted therapies. This trend is reflected in the financial performance of key players; Recordati's 'Preliminary Results for Full Year 2024' in February 2025 showed a 32.8% revenue increase in their Endocrinology franchise, reaching €321.7 million. Furthermore, Recordati reported that revenue for its Rare Diseases unit grew by 29.2% in the first half of 2025 compared to the prior period, illustrating the sector's sustained momentum.

Market Challenge

The prohibitive cost of lifelong pharmacological therapy represents a major obstacle to the growth of the Global Acromegaly Treatment Market. While somatostatin analogs and growth hormone receptor antagonists are vital for managing the disease, their high pricing creates significant accessibility barriers. Since these interventions are maintenance therapies rather than cures, they require indefinite administration, resulting in a cumulative financial burden that many healthcare budgets cannot sustain. This high cost directly limits market penetration in developing regions where reimbursement frameworks are insufficient to cover such expensive, long-term regimens.

Moreover, even in markets with established insurance systems, the economic strain is frequently shifted to patients, leading to reduced adherence and treatment discontinuation. In 2025, the HealthWell Foundation reported that patients diagnosed with acromegaly utilized an average of $2,200 in annual grant funding specifically to bridge the gap for out-of-pocket expenses. This data underscores the financial toxicity facing patients, which directly hampers the consistent consumption of therapeutics. Consequently, the market struggles to realize its full revenue potential as economic constraints prevent a large portion of the diagnosed population from accessing or maintaining necessary care.

Market Trends

The entry of generic acromegaly therapeutics is fundamentally altering the competitive landscape by dismantling the long-standing price barriers associated with branded somatostatin analogs. As patents for major biologics expire, manufacturers are introducing complex generic formulations that offer bioequivalent efficacy at reduced costs, thereby expanding treatment access for patient populations previously restricted by reimbursement limitations. This influx of cost-effective alternatives is rapidly capturing market share from originator products; according to Teva Pharmaceuticals in January 2025, their U.S. Generics business grew by 15% in 2024, a performance significantly bolstered by the launch of the first generic version of Sandostatin LAR Depot.

Concurrently, the integration of patient-centric self-administration devices is revolutionizing disease management by shifting care from clinical settings to the patient's home. Developers are coupling prolonged-release formulations with advanced delivery technologies, such as pre-filled autoinjectors, to eliminate the need for invasive injections administered by healthcare professionals. This trend addresses the burden of frequent clinic visits and associated pain, enhancing adherence and patient autonomy. Highlighting this progress, Camurus confirmed in a January 2026 press release that its novel once-monthly subcutaneous octreotide depot, Oclaiz, designed for self-administration, received marketing authorization in the European Union and the United Kingdom in 2025.

Key Market Players

• Recordati S.p.A.
• Pfizer Inc.
• Validus Pharmaceuticals LLC
• Ipsen S.A.
• Crinetics Pharmaceuticals, Inc.
• Amryt Pharma plc
• Debiopharm International SA
• ADVANZ PHARMA CORP.
• Novartis Pharmaceuticals Corporation
• Amolyt Pharma SAS

Report Scope

In this report, the Global Acromegaly Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Acromegaly Treatment Market, By Drugs

• Somatostatin Analogs
• Growth Hormone Receptor Antagonists
• Dopamine Agonists
• Combination Therapy

Acromegaly Treatment Market, By Route of administration

• Oral
• Subcutaneous
• Others

Acromegaly Treatment Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Acromegaly Treatment Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Acromegaly Treatment Market.

Available Customizations:

Global Acromegaly Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Acromegaly Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drugs (Somatostatin Analogs, Growth Hormone Receptor Antagonists, Dopamine Agonists, Combination Therapy)
  • 5.2.2. By Route of administration (Oral, Subcutaneous, Others)
  • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Acromegaly Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drugs
  • 6.2.2. By Route of administration
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Acromegaly Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drugs
      • 6.3.1.2.2. By Route of administration
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada Acromegaly Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drugs
      • 6.3.2.2.2. By Route of administration
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Acromegaly Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drugs
      • 6.3.3.2.2. By Route of administration
      • 6.3.3.2.3. By Distribution Channel

7. Europe Acromegaly Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drugs
  • 7.2.2. By Route of administration
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Acromegaly Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drugs
      • 7.3.1.2.2. By Route of administration
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. France Acromegaly Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drugs
      • 7.3.2.2.2. By Route of administration
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Acromegaly Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drugs
      • 7.3.3.2.2. By Route of administration
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Acromegaly Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drugs
      • 7.3.4.2.2. By Route of administration
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Acromegaly Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drugs
      • 7.3.5.2.2. By Route of administration
      • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Acromegaly Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drugs
  • 8.2.2. By Route of administration
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Acromegaly Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drugs
      • 8.3.1.2.2. By Route of administration
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Acromegaly Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drugs
      • 8.3.2.2.2. By Route of administration
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Japan Acromegaly Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drugs
      • 8.3.3.2.2. By Route of administration
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. South Korea Acromegaly Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drugs
      • 8.3.4.2.2. By Route of administration
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Acromegaly Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drugs
      • 8.3.5.2.2. By Route of administration
      • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Acromegaly Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drugs
  • 9.2.2. By Route of administration
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Acromegaly Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drugs
      • 9.3.1.2.2. By Route of administration
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. UAE Acromegaly Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drugs
      • 9.3.2.2.2. By Route of administration
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. South Africa Acromegaly Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drugs
      • 9.3.3.2.2. By Route of administration
      • 9.3.3.2.3. By Distribution Channel

10. South America Acromegaly Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drugs
  • 10.2.2. By Route of administration
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Acromegaly Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drugs
      • 10.3.1.2.2. By Route of administration
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Colombia Acromegaly Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drugs
      • 10.3.2.2.2. By Route of administration
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. Argentina Acromegaly Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drugs
      • 10.3.3.2.2. By Route of administration
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Acromegaly Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Recordati S.p.A.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Pfizer Inc.
• 15.3. Validus Pharmaceuticals LLC
• 15.4. Ipsen S.A.
• 15.5. Crinetics Pharmaceuticals, Inc.
• 15.6. Amryt Pharma plc
• 15.7. Debiopharm International SA
• 15.8. ADVANZ PHARMA CORP.
• 15.9. Novartis Pharmaceuticals Corporation
• 15.10. Amolyt Pharma SAS

16. Strategic Recommendations

17. About Us & Disclaimer